Share this video  

ASCO GI 2021 | Durvalumab and PET-directed CRT after induction FOLFOX for esophageal adenocarcinoma.

Geoffrey Ku • 21 Jan 2021
ASCO GI 2021
Esophageal Cancer Gastroesophageal Cancer Gastrointestinal Cancer Antibodies Durvalumab FOLFOX Telomelysin
Immuno-Oncology Radiotherapy

Geoffrey Ku, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the results of a study evaluating durvalumab, an anti-PD-L1 antibody, and PET-directed chemoradiation (CRT) after induction FOLFOX for patients with esophageal adenocarcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Disclosures

Dr Ku reports Apexigen (consulting), AstraZeneca (research support), BMS (research support, consulting), Daiichi-Sankyo (research support), Merck (research support, consulting), Oncolys (research support), Pieris (research support, consulting), Zymeworks (research support).

More from Geoffrey Ku

4:39
Latest news in gastric cancer from ASCO GI
Geoffrey Ku • 21 Jan 2021
3:11
PRS-343 in HER2-Positive Solid Tumors: A trial update
Geoffrey Ku • 24 Sep 2020
1:15
How do we treat GEJ carcinoma resistant to HER2 targeted therapies?
Geoffrey Ku • 17 Apr 2023
1:50
Durvalumab and PET-directed chemoradiation in advanced esophageal cancer
Geoffrey Ku • 17 Apr 2023

Related Videos

1:23
Future therapeutic strategies for HCC
Arndt Vogel • 9 Nov 2018
3:24
COVID-19 & the management of cancer patients
Alberto F. Sobrero • 3 Jun 2020
2:13
HER-2 conversion: a phenomenon in trastuzumab resistance
Russell Petty • 5 Nov 2019
3:40
The gut microbiome: role in causing and detecting colorectal cancer
Paul O'Toole • 29 Nov 2018
The content of VJOncology is intended for healthcare professionals